Growth opportunity Target expansion into PE and PM-CDT markets by highlighting Thrombolex's BASHIR Endovascular Catheter platform and seven FDA-cleared devices, positioning the company as a scalable solution for thromboembolic treatment in hospitals and imaging centers.

Strategic partnerships Leverage recent Series A funding and new executive leadership to pursue co-development, distribution, and OEM partnerships with large interventional device players and regional distributors to accelerate market reach in the United States and potential international markets.

Institutional validation Emphasize the commercial-stage status and strong investor backing from OrbiMed, supplemented by high-profile board appointments, to reassure hospitals, procurement, and payers about financial stability and long-term support.

Key customer segments Focus on centers treating pulmonary embolism and venous thromboembolism, including acute care hospitals and catheterization laboratories, with tailored ROI messaging around reduced procedure times, improved lysis efficacy, and potential hospital cost savings.

Competitive positioning Differentiate from peers by underscoring the differentiated pharmaco-mechanical lysis platform, FDA-cleared seven-device portfolio, and ongoing R&D trajectory to address both arterial and venous thromboembolic conditions in a growing market.